Dengue Testing Market: By Product Type (ELISA-based Tests, RT-PCR based Tests, Dengue IgG/IgM Rapid Test, and Other Tests), By End-user (Hospitals, Diagnostic Centers, and Other End-users) and Geography

Dengue Testing Market size was valued at USD 345.7 million in 2023 and is poised to grow at a CAGR of 4.2% from 2024 to 2030. Dengue testing involves various diagnostic procedures to detect dengue virus infection and assess its severity. These tests are crucial for early diagnosis and appropriate management of dengue fever, a mosquito-borne disease that affects millions globally each year. The increasing incidence of dengue fever, particularly in tropical and subtropical regions, is a key driver for the dengue testing market. According to the World Health Organization, dengue infections have increased dramatically in recent decades, with an estimated 390 million infections occurring annually. Government and healthcare professionals' initiatives to limit dengue spread are expected to boost the market's growth over the forecast period.

For instance, in May 2023 year, DoH-CHD ramped up its dengue fever campaign in Soccsksargen after the Regional Epidemiology and Surveillance Unit (RESU) recorded 854 dengue cases in the Philippines from January 1 to April 30 2023 year. Furthermore, technological advancements in testing methods, such as the development of rapid diagnostic tests and multiplex PCR assays, contribute to market growth by improving the speed and accuracy of diagnosis. The market is also benefiting from increased healthcare expenditure and a growing focus on preventive care in many countries challenges such as the lack of healthcare infrastructure in some endemic regions and the need for more sensitive and specific diagnostic tools may hinder market growth. Asia Pacific region held the major market share in 2023 and is expected to dominate the global Dengue Testing Market in the forecasted years.

Dengue Testing Market Key Developments:

In 2022, Abbott Laboratories launched the Panbio Dengue IgG/IgM Rapid Test Device, a rapid diagnostic test that can differentiate between primary and secondary dengue infections.

• As a rapid diagnostic test, it provides quick results, typically within 15-20 minutes.
• It can distinguish between primary and secondary dengue infections; it’s supposed to be an important feature as secondary infections are often more severe
• Detection of Both IgG and IgM Antibodies, where IgM antibody presence denotes recent or current infection & IgG indicates past infection, in case both are present it shows the secondary infection.

In 2023, Roche Diagnostics introduced a new multiplex PCR test that can simultaneously detect dengue, Zika, and chikungunya viruses, aiming to improve differential diagnosis in regions where these diseases co-circulate.

• ability to simultaneously detect three different viruses - dengue, Zika, and chikungunya.
• It utilizes PCR-based Technology that make it highly sensitive and highly specific